Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Embotrial-1 is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE) to assess the superiority of MMA embolization compared to conservative treatment. The intervention group is MMA embolization and comparator control group is the conservative management with best medical treatment. Patients are randomized 1:1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management of CSDH With or Without EMMA- a Randomized Control Trial

NCT04750200

Chronic Subdural Hematoma

ACTIVE_NOT_RECRUITING NA

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

NCT04372147

Chronic Subdural Hematoma At Risk of Post-operative Recurrence Burr-hole Surgery

COMPLETED NA

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

NCT04923984

Subdural Hematoma

RECRUITING NA

Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma

NCT06772740

Endovascular Treatment Chronic Subdural Hematoma

RECRUITING NA

Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma

NCT03307395

Chronic Subdural Hematoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients randomized to the experimental arm will submit to cerebral angiography and bilateral MMA embolization of the cSHD, even if it is located to only one side. The ipsilateral MMA embolization of the cSDH is allowed when the endovascular procedure cannot be performed on both sides. Patients are preferably under monitored local anesthesia or alternatively under conscious sedation or general anesthesia. Briefly, through femoral or radial artery access a standard 5 French diagnostic catheter is placed in the proximal external carotid artery and a digital subtraction angiography (DSA) is performed. Then, a microcatheter is advanced selectively under roadmap guidance into the main trunk of MMA, and superselective angiography is performed to evaluate for potentially dangerous anastomoses between MMA and ophthalmic or petrous branches prior to embolization. After collateral vessels are excluded, the MMA is occluded with PVA particles or liquid embolizing materials . The successful embolization is defined as that both frontal and parietal branch of MMA are selectively occluded and for this purpose, the microcatheter should be placed as distally as possible. It is recommended to ensure embolic materials penetrating into the capillary network of the dura to be permanently blocked. Patients randomized to the conservative arm will be clinmically monitored and eventually receive a best supportive care according to the local practice.

The trial is powered to assess superiority. When assuming the event rate of 1% in intervention group and 10% event rate in the control group, with a power of 85% and two-sided alpha of 0.05, allowing for 10% drop-outs, the estimated sample size is 300 patients in total.

The safety and efficacy interim analysis will be planned when half of the target sample (150 patients) completed 6 months follow-up. The enrollment will be stopped if the futility assessment based on estimated conditional power will be \<70%.

All patient data is registered in the electronic data capture software REDCap. This worldwide online system allows built-in logical checks and validations to promote data quality. All clinical data are entered via an encrypted connection, are anonymized, and fulfill the demands for data protection. All data entries and changes are logged in REDCap and meet the Good Clinical Practice (GCP) requirements for the use of the electronic case report form (eCRF) in medical trials. Trial coordinators, data managers and the investigators will be introduced to the platform and trained in data entry during the initial kick-of meeting prior to recruitment of the first patient. Trial staff will be provided with a personal ID.

Currently, 6 centers in Italy have been identified for the study. All the clinical investigators are board-certified and have renowned expertise in neurosurgery, neuroradiology and endovascular interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subdural Hematoma, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Embolization of the middle meningeal artery

Endovascular treatment of chronic subdural hematoma

Group Type EXPERIMENTAL

embolization of the middle meningeal artery

Intervention Type DEVICE

Embolization of the MMA is occluded with PVA particles or liquid embolizing materials

standard of care

control group will managed according to the current standard of care with "wait and see" approach and best medical treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

embolization of the middle meningeal artery

Embolization of the MMA is occluded with PVA particles or liquid embolizing materials

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No neurological deficits (Markwalder score ≤1);
* Unilateral or bilateral cSDH;
* Subdural Hematoma width ≤ 20 mm; midline shift ≤ 7mm;
* Independent functional status with mRS score ≤ 2 prior to symptom onset;
* Likely compliance of the participant in attending follow-up examination.

Exclusion Criteria

* Radiological evidence of an acute or subacute subdural hematoma, subarachnoid hemorrhage, intracerebral hematoma or epidural hematoma;
* Contraindications to angiography (end stage chronic renal disease, any sign of anatomical variations that could make MMA embolization unsafe, pregnancy);
* Life expectancy \< 1 year;
* Patients with any kind of ventricular derivation catheter.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No